C₁₆H₁₄ClN₅O₆PS₂•Na; MW 525.9; λ_max 276 nm; ε 21500; sodium salt, purity > 99% HPLC. Specially purified quality, fluorescent impurities removed. For other salt forms please inquire. Potent selective inhibitor of protein kinase G I a, I ß and especially of type II. Activates retinal cGMP channels and thus discriminates between kinase and channel effects. Absolutely resistant against mammalian cyclic nucleotide-dependent phosphodiesterases, no metabolic side effects. Significantly more lipophilic and membrane-permeant compared to Rp-cGMPS or Rp-8-Br-cGMPS. Detailed technical information and updated reference list available on request. References: Butt et al., Eur. J. Pharmacol., 269, 265 - 268 (1994); Gamm et al., J. Biol. Chem., 270, 27380 - 27388 (1996); Kramer et al., J. Neurosci., 16, 1285 - 1293 (1996).

Protected under patents US 5,625,056, DE 42 17679 & DE 3802865.4 issued or licensed exclusively to BIOLOG LSI